Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.71 |
| ▸ | CA9 | Q16790 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 5/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 4/20 | 0.58 |
| ▸ | NQO1 | P15559 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29901650 | 0.84 | CA12 (0.73) | CA12CA9LMNAHPGDALDH1A1 | |
| SCHEMBL1648027 | 0.84 | CA12 (0.73) | CA12CA9LMNAHPGDALDH1A1 | |
| SCHEMBL3527681 | 0.83 | CA12 (1.00) | CA12CA9LMNAHPGDALDH1A1 | |
| SCHEMBL30933370 | 0.83 | CA12 (1.00) | CA12CA9LMNAHPGDALDH1A1 | |
| SCHEMBL10613511 | 0.81 | CA12 (0.69) | CA12CA9LMNAHPGDALDH1A1 | |
| SCHEMBL1850238 | 0.81 | ALDH1A1 (0.56) | CA12CA9LMNAHPGDALDH1A1 | |
| SCHEMBL9278433 | 0.80 | NQO1 (0.58) | CA12CA9LMNAHPGDALDH1A1 | |
| SCHEMBL29801774 | 0.80 | ALDH1A1 (0.51) | CA12CA9LMNAHPGDALDH1A1 | |
| SCHEMBL24864745 | 0.79 | CA12 (0.65) | CA12CA9LMNAHPGDALDH1A1 | |
| SCHEMBL17169389 | 0.79 | CA12 (0.69) | CA12CA9LMNAHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0550493-A1 | ANTHELMINTIC AND ANTICOCCIDAL 3-CARBAMOYL-4-HYDROXYCOUMARINS, METHOD OF USE AND COMPOSITIONS. | UPJOHN CO (US) | 1993-07-14 | — | — | EP | claimed |
| WO-1992006083-A1 | ANTHELMINTIC AND ANTICOCCIDAL 3-CARBAMOYL-4-HYDROXYCOUMARINS, METHOD OF USE AND COMPOSITIONS | THE UPJOHN COMPANY (US) | 1992-04-16 | — | — | WO | claimed |
| US-4766144-A | 3-carbamoyl-4-hydroxy-coumarins for combating parasitic heiminths | BAYER AKTIENGESELLSCHAFT (DE) | 1988-08-23 | — | — | US | claimed |
| EP-0241834-A2 | Use of 3-carbamoyl-4-hydroxy-cumarines in combating parasiticidal helminths, 3-carbamoyl-4-hydroxy-cumarines and their preparation | BAYER AG (DE) | 1987-10-21 | — | — | EP | claimed |
| EP-0038427-A1 | 3-Carbamoyl-4-hydroxy-cumarines, process for their preparation and their use as pesticides | BAYER AG (DE) | 1981-10-28 | — | — | EP | claimed |
| EP-2295053-B1 | Novel 2H-chromen-2-one-3-carboxamides for medical uses | INST MATERIA MEDICA CAMS (CN) | 2016-10-19 | — | — | EP | disclosed |
| US-20110263642-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | FIBROGEN, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2341904-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | Fibrogen, Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010024908-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | FIBROGEN, INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| EP-1664332-A4 | KINASE AND PHOSPHATASE ASSAYS | INVITROGEN CORP (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008054695-A2 | COMPOSITION AND METHOD FOR ETIOLOGICAL TREATMENT AND PREVENTION OF DISEASES AND/OR COMPLICATIONS ASSOCIATED WITH CHRONIC GLUCOSE METABOLISM DESTABILIZATION | GUFFEY MANNING V (US) | 2008-05-08 | — | — | WO | disclosed |
| US-20080102137-A1 | Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization | GUFFEY MANNING V R | 2008-05-01 | — | — | US | disclosed |
| EP-0241834-A3 | USE OF 3-CARBAMOYL-4-HYDROXY-CUMARINES IN COMBATING PARASITICIDAL HELMINTHS, 3-CARBAMOYL-4-HYDROXY-CUMARINES AND THEIR PREPARATION | BAYER AG (DE) | 1988-10-26 | — | — | EP | disclosed |
| US-4766144-A | 3-carbamoyl-4-hydroxy-coumarins for combating parasitic heiminths | BAYER AKTIENGESELLSCHAFT (DE) | 1988-08-23 | — | — | US | disclosed |
| US-4766144-A | 3-carbamoyl-4-hydroxy-coumarins for combating parasitic heiminths | BAYER AKTIENGESELLSCHAFT (DE) | 1988-08-23 | — | — | US | disclosed |
| EP-0241834-A2 | Use of 3-carbamoyl-4-hydroxy-cumarines in combating parasiticidal helminths, 3-carbamoyl-4-hydroxy-cumarines and their preparation | BAYER AG (DE) | 1987-10-21 | — | — | EP | disclosed |
| EP-0241834-A2 | Use of 3-carbamoyl-4-hydroxy-cumarines in combating parasiticidal helminths, 3-carbamoyl-4-hydroxy-cumarines and their preparation | BAYER AG (DE) | 1987-10-21 | — | — | EP | disclosed |
| EP-0038427-A1 | 3-Carbamoyl-4-hydroxy-cumarines, process for their preparation and their use as pesticides | BAYER AG (DE) | 1981-10-28 | — | — | EP | disclosed |
| EP-0038427-A1 | 3-Carbamoyl-4-hydroxy-cumarines, process for their preparation and their use as pesticides | BAYER AG (DE) | 1981-10-28 | — | — | EP | disclosed |
| EP-0038427-A1 | 3-Carbamoyl-4-hydroxy-cumarines, process for their preparation and their use as pesticides | BAYER AG (DE) | 1981-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263642-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | PMP22, MAG, NEFM | CA12 821/4885CA9 2529/4885LMNA 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.